ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML

被引：0
|
作者：
Golla, Upendarrao
Patel, Satyam
Tukaramrao, Diwakar B.
Hengst, Jeremy
Restrepo, Juliana
Amin, Shantu
Desai, Dhimant
Dovat, Sinisa
Claxton, David
Sharma, Arati
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2677
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2-and FLT3-Mutated Acute Myeloid Leukemia
    Seipel, Katja
    Bruegger, Yvo
    Mandhair, Harpreet
    Bacher, Ulrike
    Pabst, Thomas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [42] Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
    Xu, Xi
    Ma, Weiwei
    Qiu, Guo
    Xuan, Li
    He, Chong
    Zhang, Tian
    Wang, Jian
    Liu, Qifa
    BIOLOGY-BASEL, 2023, 12 (10):
  • [43] Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
    Montero, Joan
    Stephansky, Jason
    Cai, Tianyu
    Griffin, Gabriel K.
    Cabal-Hierro, Lucia
    Togami, Katsuhiro
    Hogdal, Leah J.
    Galinsky, Ilene
    Morgan, Elizabeth A.
    Aster, Jon C.
    Davids, Matthew S.
    LeBoeuf, Nicole R.
    Stone, Richard M.
    Konopleva, Marina
    Pemmaraju, Naveen
    Letai, Anthony
    Lane, Andrew A.
    CANCER DISCOVERY, 2017, 7 (02) : 156 - 164
  • [44] Targeting BCL2 family protein phosphorylation in venetoclax resistant lymphoid malignancies
    Chong, Stephen J.
    Zhu, Fen
    Lai, Jolin X.
    Hackett, Liam
    Collins, Mary C.
    Pervaiz, Shazib
    Coppe, Jean-Philippe
    Davids, Matthew S.
    CANCER RESEARCH, 2022, 82 (12)
  • [45] The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
    Le Xuan Truong Nguyen
    Troadec, Estelle
    Kalvala, Arjun
    Kumar, Bijender
    Dinh Hoa Hoang
    Viola, Domenico
    Zhang, Bin
    Dang Quan Nguyen
    Aldoss, Ibrahim
    Ghoda, Lucy
    Budde, Elizabeth
    Pichiorri, Flavia
    Rosen, Steven
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) : 14040 - 14049
  • [46] Expression of BCL2 alternative proteins and association with outcome in CLL patients with venetoclax
    Furqan, Fateeha
    Schlette, Ellen J.
    Vega, Francisco
    Wistuba, Ignacio I.
    Soto, Luisa M.
    Piubelli, Mario L.
    Wierda, William G.
    Ferrajoli, Alessandra
    Strati, Paolo
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
    Brown, Fiona C.
    Wang, Xin
    Birkinshaw, Richard
    Chua, Chong Chyn
    Morley, Thomas
    Kasapgil, Sila
    Pomilio, Giovanna
    Blombery, Piers
    Huang, David C. S.
    Czabotar, Peter
    Priore, Salvatore F.
    Yang, Guang
    Carroll, Martin
    Wei, Andrew H.
    Perl, Alexander E.
    BLOOD ADVANCES, 2025, 9 (01) : 127 - 131
  • [48] Acute toxicity analysis of Disarib, an inhibitor of BCL2
    Shivangi Sharma
    Kontham Kulangara Varsha
    Susmita Kumari
    Vidya Gopalakrishnan
    Anjana Elizabeth Jose
    Bibha Choudhary
    Kempegowda Mantelingu
    Sathees C. Raghavan
    Scientific Reports, 10
  • [49] Artemisinins enhanced the antileukemic efficacy of BCL2 inhibitors
    Moses, Blake S.
    Fox, Jennifer M.
    Chen, Xiaochun
    Tyner, Jeffrey W.
    Posner, Gary H.
    Bailey, Patrick
    Civin, Curt I.
    CANCER RESEARCH, 2017, 77
  • [50] Acute toxicity analysis of Disarib, an inhibitor of BCL2
    Sharma, Shivangi
    Varsha, Kontham Kulangara
    Kumari, Susmita
    Gopalakrishnan, Vidya
    Jose, Anjana Elizabeth
    Choudhary, Bibha
    Mantelingu, Kempegowda
    Raghavan, Sathees C.
    SCIENTIFIC REPORTS, 2020, 10 (01)
12345